An article in BNA’s Patent, Trademark & Copyright Journal about the recent Burrill Personalized Medicine Meeting quoted Ken Chahine, technologist in residence and a visiting professor with the BioLaw Project at the University of Utah S.J. Quinney College of Law.
Referring to the questions about what can be patented in the aftermath of various contradictory rulings, Chahine said, “There’s a little bit of potential triple whammy here where you can’t patent the isolated gene, you can’t patent the correlation to determine whether someone’s predisposed to something, and you can’t patent the algorithm no matter how complicated it is. And so that’s really where we stand right now.’’
The entire Patent, Trademark & Copyright Journal article can be read here.